emodin
cell
arrest
apoptosisinduc
compound
wide
distribut
differ
plant
rhubarb
alo
lichen
terrestri
fungi
also
isol
marinederiv
fungi
marin
spongeassoci
fungi
studi
design
synthes
novel
seri
emodin
deriv
bind
emodin
amino
acid
use
linker
vari
length
composit
evalu
antiprolif
activ
use
cell
human
hepat
carcinoma
cell
human
breast
cancer
human
normal
liver
cell
deriv
show
moder
potent
antiprolif
activ
notabl
compound
exhibit
potent
antiprolif
activ
cell
half
maxim
inhibitori
concentr
ic
valu
enhanc
compar
parent
compound
emodin
ic
also
exhibit
better
select
antiprolif
activ
specif
emodin
moreov
experi
demonstr
compound
display
signific
efficaci
induc
apoptosi
mitochondri
pathway
via
releas
cytochrom
c
mitochondria
subsequ
activ
induc
cell
arrest
phase
well
suppress
cell
migrat
tumor
cell
preliminari
result
suggest
compound
could
promis
lead
compound
discoveri
novel
antitumor
drug
potenti
investig
anticanc
drug
molecul
activ
wide
report
recent
decad
pharmacolog
studi
shown
emodin
capabl
inhibit
cellular
prolifer
induc
cell
differenti
apoptosi
activ
caspas
cascad
pathway
mitochondri
death
pathway
differ
cancer
cell
emodin
figur
natur
occur
anthraquinon
deriv
wide
distribut
differ
plant
rhubarb
alo
lichen
terristri
fungi
also
isol
marinederiv
fungi
marin
spongeassoci
fungi
also
activ
ingredi
chines
medicin
herb
use
treatment
constip
jaundic
gastrointestin
hemorrhag
ulcer
emodin
tricycl
planar
chromophor
skeleton
certain
antitumor
antibiot
daunorubicin
doxorubicin
epirubicin
sever
synthet
analog
distribut
mitoxantron
pixantron
figur
use
clinic
treatment
variou
cancer
mani
report
demonstr
emodin
possess
wide
spectrum
pharmacolog
effect
antitumour
antiinflammatori
antivir
antibacteri
antiallerg
antiosteoporot
antidiabet
immunosuppress
neuroprotect
hepatoprotect
activ
etc
among
effect
antitumor
antiosteoporot
antidiabet
immunosuppress
neuroprotect
hepatoprotect
activ
etc
among
effect
antitumor
activ
wide
report
recent
decad
pharmacolog
studi
shown
emodin
capabl
inhibit
cellular
prolifer
induc
cell
differenti
apoptosi
activ
caspas
cascad
pathway
mitochondri
death
pathway
differ
cancer
cell
chemic
transform
bioactiv
compound
natur
product
one
common
approach
drug
discoveri
improv
therapeut
properti
date
antitumor
activ
emodin
improv
structur
modif
mainli
side
chain
includ
methyl
hydroxyl
andor
aryl
ring
group
exampl
wang
et
al
report
emodin
quaternari
ammonium
salt
deriv
show
signific
anticanc
activ
hepatoma
cell
xing
et
al
report
effect
emodin
rhamnosid
deriv
human
cancer
cell
tan
et
al
report
dnabind
pyrazol
emodin
deriv
howev
emodin
ideal
chemotherapeut
agent
cancer
due
poor
bioavail
low
solubl
high
toxic
vivo
bioavail
drug
posit
correl
solubl
thu
amino
acid
possess
carboxyl
amino
function
ideal
moieti
structur
modif
bioactiv
natur
product
amino
acid
interact
biomolecul
via
secondari
interact
hydrogen
bond
improv
pharmacolog
profil
potenc
bioavail
exampl
conjug
amino
acid
betulin
acid
abl
improv
watersolubl
well
antimelanoma
activ
find
prompt
us
design
synthes
seri
novel
emodin
deriv
link
variou
amino
acid
tfa
salt
figur
among
deriv
compound
deriv
r
acid
exhibit
antiprolif
activ
cell
cell
prompt
us
screen
differ
length
diol
linker
acid
emodin
result
also
suggest
compar
compound
compound
exhibit
slightli
potent
chemic
transform
bioactiv
compound
natur
product
one
common
approach
drug
discoveri
improv
therapeut
properti
date
antitumor
activ
emodin
improv
structur
modif
mainli
side
chain
includ
methyl
hydroxyl
andor
aryl
ring
group
exampl
wang
et
al
report
emodin
quaternari
ammonium
salt
deriv
show
signific
anticanc
activ
hepatoma
cell
xing
et
al
report
effect
emodin
rhamnosid
deriv
human
cancer
cell
tan
et
al
report
dnabind
pyrazol
emodin
deriv
howev
emodin
ideal
chemotherapeut
agent
cancer
due
poor
bioavail
low
solubl
high
toxic
vivo
bioavail
drug
posit
correl
solubl
thu
amino
acid
possess
carboxyl
amino
function
ideal
moieti
structur
modif
bioactiv
natur
product
amino
acid
interact
biomolecul
via
secondari
interact
hydrogen
bond
improv
pharmacolog
profil
potenc
bioavail
exampl
conjug
amino
acid
betulin
acid
abl
improv
watersolubl
well
antimelanoma
activ
find
prompt
us
design
synthes
seri
novel
emodin
deriv
link
variou
amino
acid
tfa
salt
figur
antiosteoporot
antidiabet
immunosuppress
neuroprotect
hepatoprotect
activ
etc
among
effect
antitumor
activ
wide
report
recent
decad
pharmacolog
studi
shown
emodin
capabl
inhibit
cellular
prolifer
induc
cell
differenti
apoptosi
activ
caspas
cascad
pathway
mitochondri
death
pathway
differ
cancer
cell
chemic
transform
bioactiv
compound
natur
product
one
common
approach
drug
discoveri
improv
therapeut
properti
date
antitumor
activ
emodin
improv
structur
modif
mainli
side
chain
includ
methyl
hydroxyl
andor
aryl
ring
group
exampl
wang
et
al
report
emodin
quaternari
ammonium
salt
deriv
show
signific
anticanc
activ
hepatoma
cell
xing
et
al
report
effect
emodin
rhamnosid
deriv
human
cancer
cell
tan
et
al
report
dnabind
pyrazol
emodin
deriv
howev
emodin
ideal
chemotherapeut
agent
cancer
due
poor
bioavail
low
solubl
high
toxic
vivo
bioavail
drug
posit
correl
solubl
thu
amino
acid
possess
carboxyl
amino
function
ideal
moieti
structur
modif
bioactiv
natur
product
amino
acid
interact
biomolecul
via
secondari
interact
hydrogen
bond
improv
pharmacolog
profil
potenc
bioavail
exampl
conjug
amino
acid
betulin
acid
abl
improv
watersolubl
well
antimelanoma
activ
find
prompt
us
design
synthes
seri
novel
emodin
deriv
link
variou
amino
acid
tfa
salt
figur
among
deriv
compound
deriv
r
acid
exhibit
antiprolif
activ
cell
cell
prompt
us
screen
differ
length
diol
linker
acid
emodin
result
also
suggest
compar
compound
compound
exhibit
slightli
potent
among
deriv
compound
deriv
r
acid
exhibit
antiprolif
activ
cell
cell
prompt
us
screen
differ
length
diol
linker
acid
emodin
result
also
suggest
compar
compound
compound
exhibit
slightli
potent
antiprolif
activ
cell
cell
follow
anticanc
mechan
compound
evalu
cell
novel
seri
emodin
deriv
link
amino
acid
design
synthes
synthesi
strategi
emodin
deriv
outlin
scheme
synthesi
compound
compound
subject
alkyl
reaction
cs
co
dmf
result
compound
coupl
reaction
convent
coupl
condit
dccdmap
compound
variou
commerci
avail
nboc
protect
amino
acid
result
format
condens
product
remov
protect
group
usinng
tfa
dcm
target
compound
obtain
tfa
salt
molecul
x
peer
review
antiprolif
activ
cell
cell
follow
anticanc
mechan
compound
evalu
cell
novel
seri
emodin
deriv
link
amino
acid
design
synthes
synthesi
strategi
emodin
deriv
outlin
scheme
synthesi
compound
compound
subject
alkyl
reaction
dmf
result
compound
coupl
reaction
convent
coupl
condit
dccdmap
compound
variou
commerci
avail
nboc
protect
amino
acid
result
format
condens
product
remov
protect
group
usinng
tfa
dcm
target
compound
obtain
tfa
salt
follow
dccdmap
coupl
condit
deprotect
tfa
dcm
synthesi
compound
target
compound
obtain
tfa
salt
scheme
scheme
synthesi
compound
reagent
condit
cs
co
dmf
c
b
variou
nboc
amino
acid
dcc
dcm
c
ii
tfa
dcm
rt
two
step
follow
dccdmap
coupl
condit
deprotect
tfa
dcm
synthesi
compound
target
compound
obtain
tfa
salt
scheme
product
coupl
formaldehyd
aqueou
solut
reduc
util
provid
tfa
salt
yield
respect
shown
scheme
employ
rout
synthesi
compound
compound
obtain
tfa
salt
scheme
synthesi
compound
reagent
condit
variou
hydroxyalkyl
bromid
iodid
dmf
b
rsnbocalaoh
dcc
dcm
ii
tfa
dcm
rt
two
step
vitro
antiprolif
activ
novel
synthes
compound
evalu
cell
cell
celltiterglo
luminesc
cell
viabil
assay
use
paclitaxel
clinic
use
drug
posit
control
emodin
compound
also
includ
comparison
shown
tabl
emodin
show
weak
inhibitori
activ
cell
cell
valu
respect
compar
emodin
compound
show
reduc
activ
due
introduct
hydroxyethyl
group
emodin
among
compound
contain
amino
acid
group
worth
note
compound
display
potent
activ
emodin
compound
gli
group
display
near
doubl
activ
emodin
cell
slightli
decreas
activ
cell
compound
dala
group
display
potent
antiprolif
activ
cell
cell
valu
respect
compound
lala
group
display
slightli
weaker
activ
compound
still
display
stronger
activ
emodin
compound
contain
alkyl
chain
amino
acid
group
also
display
stronger
inhibitori
activ
emodin
overal
except
compound
compound
cyclic
alkyl
amino
acid
group
display
wors
inhibitori
activ
emodin
especi
compound
contain
heterocycl
interestingli
compound
contain
cyclopentan
amino
acid
group
display
higher
antiprolif
activ
cell
cell
valu
scheme
synthesi
compound
reagent
condit
bocnmer
salaoh
dcc
dcm
c
ii
tfa
dcm
rt
two
step
b
formaldehyd
aqueou
solut
nabh
cn
meoh
rt
product
coupl
formaldehyd
aqueou
solut
reduc
util
nabh
cn
provid
tfa
salt
yield
respect
shown
scheme
employ
rout
synthesi
compound
compound
obtain
tfa
salt
product
coupl
formaldehyd
aqueou
solut
reduc
util
provid
tfa
salt
yield
respect
shown
scheme
employ
rout
synthesi
compound
compound
obtain
tfa
salt
vitro
antiprolif
activ
novel
synthes
compound
evalu
cell
cell
celltiterglo
luminesc
cell
viabil
assay
use
paclitaxel
clinic
use
drug
posit
control
emodin
compound
also
includ
comparison
shown
tabl
emodin
show
weak
inhibitori
activ
cell
cell
valu
respect
compar
emodin
compound
show
reduc
activ
due
introduct
hydroxyethyl
group
emodin
among
compound
contain
amino
acid
group
worth
note
compound
display
potent
activ
emodin
compound
gli
group
display
near
doubl
activ
emodin
cell
slightli
decreas
activ
cell
compound
dala
group
display
potent
antiprolif
activ
cell
cell
valu
respect
compound
lala
group
display
slightli
weaker
activ
compound
still
display
stronger
activ
emodin
compound
contain
alkyl
chain
amino
acid
group
also
display
stronger
inhibitori
activ
emodin
overal
except
compound
compound
cyclic
alkyl
amino
acid
group
display
wors
inhibitori
activ
emodin
especi
compound
contain
heterocycl
interestingli
compound
contain
cyclopentan
amino
acid
group
display
higher
antiprolif
activ
cell
cell
valu
vitro
antiprolif
activ
novel
synthes
compound
evalu
cell
cell
celltiterglo
luminesc
cell
viabil
assay
use
paclitaxel
clinic
use
drug
posit
control
emodin
compound
also
includ
comparison
shown
tabl
emodin
show
weak
inhibitori
activ
cell
cell
ic
valu
respect
compar
emodin
compound
show
reduc
activ
due
introduct
hydroxyethyl
group
emodin
among
compound
contain
amino
acid
group
worth
note
compound
display
potent
activ
emodin
compound
gli
group
display
near
doubl
activ
emodin
cell
slightli
decreas
activ
cell
compound
dala
group
display
potent
antiprolif
activ
cell
cell
ic
valu
respect
compound
lala
group
display
slightli
weaker
activ
compound
still
display
stronger
activ
emodin
compound
contain
alkyl
chain
amino
acid
group
also
display
stronger
inhibitori
activ
emodin
overal
except
compound
compound
cyclic
alkyl
amino
acid
group
display
wors
inhibitori
activ
emodin
especi
compound
contain
heterocycl
interestingli
compound
contain
cyclopentan
amino
acid
group
display
higher
antiprolif
activ
cell
cell
ic
valu
respect
compound
dand
lala
group
exhibit
similar
inhibitori
activ
compound
compar
emodin
compound
aryl
phenyl
substitut
phenyl
benzyl
substitut
benzyl
etc
amino
acid
group
display
enhanc
activ
vari
degre
test
two
cancer
cell
line
ic
valu
rang
follow
initi
result
perform
modif
compound
improv
antiprolif
activ
thu
monoand
dimethyl
amino
moieti
amino
acid
afford
compound
unfortun
modif
led
decreas
activ
vari
degre
cell
line
ic
valu
rang
shown
tabl
notabl
compound
display
activ
reduct
cell
line
compar
emodin
result
reveal
nh
moieti
favor
improv
antiprolif
activ
preliminari
explan
amino
group
interact
biomolecul
improv
antiprolif
activ
via
format
hydrogen
bond
monoor
dimethyl
amino
group
might
weaken
trend
hydrogen
bond
decreas
antiprolif
activ
next
shown
tabl
link
group
compound
optim
increas
linker
length
compound
one
addit
methylen
group
result
compound
display
enhanc
potenc
inhibit
cell
growth
cell
cell
howev
compound
initi
fail
increas
potenc
cell
growth
inhibit
test
cancer
cell
line
success
address
increas
linker
length
use
addit
methylen
bridg
hand
elong
linker
two
four
ethanediol
group
result
compound
show
decreas
activ
compar
compound
three
pair
compound
possess
stronger
antiprolif
activ
screen
cytotox
activ
preform
human
normal
liver
cell
vitro
shown
tabl
parent
compound
emodin
exhibit
stronger
cytotox
activ
cell
ic
valu
cancer
cell
line
ic
cell
ic
cell
howev
six
compound
exhibit
weaker
cytotox
activ
cell
compar
correspond
cancer
cell
line
final
chose
investig
mechan
action
compound
strongest
antiprolif
activ
cell
lack
select
cytotox
main
factor
hinder
convent
chemotherapeut
agent
thu
evalu
select
antiprolif
activ
compound
select
index
si
cancer
normal
cell
calcul
result
summar
tabl
si
calcul
divid
ic
valu
normal
cell
ic
valu
cancer
cell
emodin
display
stronger
cytotox
activ
si
valu
respect
indic
normal
cell
cancer
cell
would
kill
howev
compound
exhibit
weaker
cytotox
activ
si
valu
respect
mean
exhibit
better
select
antiprolif
activ
specif
emodin
order
verifi
whether
compound
abl
induc
apoptosi
cell
util
fitcannexin
vpi
stain
estim
percentag
apoptot
cell
flow
cytometri
note
concentrationdepend
increas
percentag
apoptot
cell
cell
treat
compound
h
concentr
shown
figur
apoptot
cell
present
control
panel
contrast
percentag
apoptot
cell
increas
treatment
compound
h
increas
treatment
concentr
illustr
figur
quantit
analysi
apoptosi
strongli
suggest
treatment
compound
effect
induc
apoptosi
cell
concentrationdepend
manner
comparison
control
order
verifi
whether
compound
abl
induc
apoptosi
cell
util
fitcannexin
vpi
stain
estim
percentag
apoptot
cell
flow
cytometri
note
concentrationdepend
increas
percentag
apoptot
cell
cell
treat
compound
h
concentr
shown
figur
apoptot
cell
present
control
panel
contrast
percentag
apoptot
cell
increas
treatment
compound
h
increas
treatment
concentr
illustr
figur
quantit
analysi
apoptosi
strongli
suggest
treatment
compound
effect
induc
apoptosi
cell
concentrationdepend
manner
comparison
control
statist
signific
determin
twotail
student
ttest
denot
p
denot
p
respect
supplementari
tabl
c
e
western
blot
analysi
effect
compound
level
bax
cytochrom
c
express
cell
f
equal
amount
protein
load
sdspage
gel
western
blot
analysi
data
express
mean
sd
percentag
apoptot
cell
three
independ
experi
statist
signific
determin
twotail
student
ttest
denot
p
denot
p
denot
p
respect
supplementari
tabl
verifi
molecular
mechan
apoptosi
induct
compound
perform
western
blot
assay
well
known
famili
proapoptot
antiapoptot
quantit
analysi
apoptosi
data
express
mean
sd
percentag
apoptot
cell
three
independ
experi
statist
signific
determin
twotail
student
ttest
denot
p
denot
p
respect
supplementari
tabl
c
e
western
blot
analysi
effect
compound
level
bax
cytochrom
c
express
cell
f
equal
amount
protein
load
sdspage
gel
western
blot
analysi
data
express
mean
sd
percentag
apoptot
cell
three
independ
experi
statist
signific
determin
twotail
student
ttest
denot
p
denot
p
denot
p
respect
supplementari
tabl
verifi
molecular
mechan
apoptosi
induct
compound
perform
western
blot
assay
well
known
famili
proapoptot
antiapoptot
protein
regul
mitochondri
pathway
apoptosi
famili
protein
stimul
permeabil
mitochondri
outer
membran
result
releas
cytochrom
c
cytosol
turn
promot
activ
caspas
cascad
activ
caspas
cascad
ultim
lead
induct
apoptot
cell
death
shown
figur
comparison
control
cell
compound
induc
increas
level
bax
decreas
express
concentrationdepend
manner
meanwhil
releas
cytochrom
c
mitochondria
increas
treatment
compound
procaspas
procaspas
decreas
treatment
indic
caspas
caspas
activ
shown
figur
f
increas
express
cleav
treatment
provid
evid
compound
induc
cell
apoptosi
mitochondri
pathway
concentrationdepend
manner
apoptosi
process
summar
follow
mitochondri
apoptosisinduc
channel
mac
cell
form
proapoptot
protein
bax
treatment
compound
format
mac
led
releas
cytochrom
c
mitochondria
cytochrom
c
releas
bind
apoptot
proteas
activ
atp
bind
creat
protein
complex
known
apoptosom
apoptosom
cleav
activ
form
initi
turn
activ
effector
final
result
cell
apoptosi
examin
compound
suppress
growth
cell
effect
compound
cell
cycl
distribut
differ
concentr
investig
flow
cytometr
analysi
follow
stain
dna
propidium
iodid
pi
result
typic
experi
shown
figur
determin
flow
cytometri
exposur
cell
compound
h
result
obviou
increas
percentag
cell
phase
comparison
control
treatment
compound
result
increas
phase
cell
compar
control
invers
phase
cell
popul
decreas
compar
control
therefor
compound
result
signific
phase
arrest
concentrationdepend
manner
concomit
decreas
number
cell
phase
cycl
protein
regul
mitochondri
pathway
apoptosi
famili
protein
stimul
permeabil
mitochondri
outer
membran
result
releas
cytochrom
c
cytosol
turn
promot
activ
caspas
cascad
activ
caspas
cascad
ultim
lead
induct
apoptot
cell
death
shown
figur
comparison
control
cell
compound
induc
increas
level
bax
decreas
express
concentrationdepend
manner
meanwhil
releas
cytochrom
c
mitochondria
increas
treatment
compound
procaspas
procaspas
decreas
treatment
indic
caspas
caspas
activ
shown
figur
f
increas
express
cleav
treatment
provid
evid
compound
induc
cell
apoptosi
mitochondri
pathway
concentrationdepend
manner
apoptosi
process
summar
follow
mitochondri
apoptosisinduc
channel
mac
cell
form
proapoptot
protein
bax
treatment
compound
format
mac
led
releas
cytochrom
c
mitochondria
cytochrom
c
releas
bind
apoptot
proteas
activ
atp
bind
creat
protein
complex
known
apoptosom
apoptosom
cleav
activ
form
initi
turn
activ
effector
final
result
cell
apoptosi
examin
compound
suppress
growth
cell
effect
compound
cell
cycl
distribut
differ
concentr
investig
flow
cytometr
analysi
follow
stain
dna
propidium
iodid
pi
result
typic
experi
shown
figur
determin
flow
cytometri
exposur
cell
compound
h
result
obviou
increas
percentag
cell
phase
comparison
control
treatment
compound
result
increas
phase
cell
compar
control
invers
phase
cell
popul
decreas
compar
control
therefor
compound
result
signific
phase
arrest
concentrationdepend
manner
concomit
decreas
number
cell
phase
cycl
tabl
evalu
effect
compound
cancer
migrat
wound
heal
assay
conduct
determin
whether
compound
could
prevent
cell
migrat
cultur
cell
h
presenc
absenc
compound
pipett
tip
streak
cell
cultur
result
cell
defici
space
territori
recov
cell
use
observ
migrat
inhibit
capabl
compound
empti
space
reduc
significantli
size
absenc
compound
cell
prolifer
migrat
result
indic
compound
suppress
mobil
tumor
cell
concentrationdepend
manner
figur
cell
cycl
distribut
treatment
compound
data
express
mean
sd
percentag
apoptot
cell
three
independ
experi
statist
signific
determin
twotail
student
ttest
denot
p
denot
p
ns
mean
signific
respect
supplementari
tabl
evalu
effect
compound
cancer
migrat
wound
heal
assay
conduct
determin
whether
compound
could
prevent
cell
migrat
cultur
cell
h
presenc
absenc
compound
pipett
tip
streak
cell
cultur
result
cell
defici
space
territori
recov
cell
use
observ
migrat
inhibit
capabl
compound
empti
space
reduc
significantli
size
absenc
compound
cell
prolifer
migrat
result
indic
compound
suppress
mobil
tumor
cell
concentrationdepend
manner
figur
tabl
start
materi
reagent
purchas
commerci
supplier
use
without
purif
emodin
extract
polygonum
cuspidatum
purchas
china
xian
sinoherb
biotechnolog
co
ltd
xian
china
reaction
monitor
thinlay
chromatographi
tlc
aluminum
sheet
silica
gel
e
merck
darmstadt
germani
compound
visual
uv
light
column
chromatographi
carri
use
silica
gel
mesh
reaction
solvent
dri
prior
use
accord
standard
procedur
primari
reagent
commerci
avail
silica
gel
chromatographi
solvent
analyt
grade
nmr
spectra
record
spectromet
bruker
biospin
switzerlahd
mhz
hnmr
mhz
cnmr
mhz
fnmr
tm
intern
standard
chemic
shift
express
ppm
coupl
constant
j
hz
multipl
indic
follow
singlet
doublet
triplet
p
quintet
dd
doublet
doublet
br
broad
singlet
etc
mass
spectra
obtain
agil
seri
lcmsd
trap
mass
spectromet
esim
agil
santa
clara
ca
usa
tabl
start
materi
reagent
purchas
commerci
supplier
use
without
purif
emodin
extract
polygonum
cuspidatum
purchas
china
xian
sinoherb
biotechnolog
co
ltd
xian
china
reaction
monitor
thinlay
chromatographi
tlc
aluminum
sheet
silica
gel
e
merck
darmstadt
germani
compound
visual
uv
light
column
chromatographi
carri
use
silica
gel
mesh
reaction
solvent
dri
prior
use
accord
standard
procedur
primari
reagent
commerci
avail
silica
gel
chromatographi
solvent
analyt
grade
nmr
spectra
record
dmsod
spectromet
bruker
biospin
switzerlahd
mhz
hnmr
mhz
cnmr
mhz
fnmr
tm
intern
standard
chemic
shift
express
ppm
coupl
constant
j
hz
multipl
indic
follow
singlet
doublet
triplet
p
quintet
dd
doublet
doublet
br
broad
singlet
etc
mass
spectra
obtain
agil
seri
lcmsd
trap
mass
spectromet
esim
agil
santa
clara
ca
usa
mixtur
emodin
g
mmol
dri
dmf
ml
ad
cs
co
g
mmol
g
mmol
room
temperatur
stir
h
c
result
mixtur
evapor
reduc
pressur
mix
water
ml
ph
valu
aqueou
phase
adjust
around
hydrochlor
acid
solut
yellow
precipit
collect
wash
water
give
crude
product
purif
tritur
twice
ethyl
acet
ml
filter
afford
compound
g
brown
solid
gener
procedur
prepar
compound
mixtur
compound
mmol
dri
dichloromethan
ml
ad
variou
nboc
amino
acid
mmol
dicyclohexyl
carbodiimid
dcc
mmol
n
ndimethlyamino
pyridin
dmap
mmol
c
stir
min
h
c
tlc
analysi
show
complet
consumpt
compound
result
mixtur
ad
dropwis
tfa
ml
temperatur
kept
stir
anther
h
insolubl
side
product
filter
filtrat
evapor
give
residu
purifi
revers
phase
flash
chromatographi
follow
condit
column
spheric
g
mobil
phase
water
plu
mm
tfa
mobil
phase
b
acn
flow
rate
mlmin
gradient
b
gradient
min
b
gradient
min
detector
nm
fraction
contain
desir
product
collect
around
b
concentr
reduc
pressur
afford
compound
yield
ethoxi
accord
gener
procedur
compound
treat
nbocglycin
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
ethoxi
accord
gener
procedur
compound
treat
nboclalanin
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
ethoxi
accord
gener
procedur
compound
treat
nbocotertbutyllserin
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
r
ethoxi
accord
gener
procedur
compound
treat
nbocdvalin
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
ethoxi
accord
gener
procedur
compound
treat
nbocaiboh
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
br
br
ethoxi
carbonyl
cyclopropanaminium
accord
gener
procedur
compound
treat
bocamino
cyclopropanecarboxyl
acid
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
br
ethoxi
carbonyl
cyclobutanaminium
accord
gener
procedur
compound
treat
bocamino
cyclobutanecarboxyl
acid
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
br
ethoxi
carbonyl
accord
gener
procedur
compound
treat
acid
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
br
ethoxi
carbonyl
cyclopentanaminium
accord
gener
procedur
compound
treat
nbocaminocyclopentanecarboxyl
acid
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
br
r
ethoxi
carbonyl
pyrrolidinium
accord
gener
procedur
compound
treat
nbocdprolin
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
j
ethoxi
carbonyl
pyrrolidinium
accord
gener
procedur
compound
treat
nboclprolin
purifi
revers
phase
flash
chromatographi
give
compound
r
ethoxi
accord
gener
procedur
compound
treat
nbocdphenylglycin
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
br
r
ethoxi
accord
gener
procedur
compound
treat
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
br
ethoxi
accord
gener
procedur
compound
treat
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
br
r
ethoxi
accord
gener
procedur
compound
treat
r
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
br
ethoxi
accord
gener
procedur
compound
treat
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
mhz
dmsod
br
r
ethoxi
accord
gener
procedur
compound
treat
nbocdphenylalanin
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
br
ethoxi
accord
gener
procedur
compound
treat
nboclphenylalanin
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
br
r
ethoxi
accord
gener
procedur
compound
treat
nbocotertbutylltyrosin
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
j
ethoxi
accord
gener
procedur
compound
treat
nbocltyrosin
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
j
r
ethoxi
accord
gener
procedur
compound
treat
bocnmethyldalanin
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
br
ethoxi
accord
gener
procedur
compound
treat
bocnmethyllalanin
purifi
revers
phase
flash
chromatographi
give
compound
yellow
solid
yield
hnmr
br
br
gener
procedur
b
prepar
compound
solut
compound
mg
mmol
paraformaldehyd
aqueou
solut
mg
mmol
meoh
ml
ad
nabh
cn
mg
mmol
c
stir
h
room
temperatur
reaction
quench
tfa
ml
result
reaction
solut
use
directli
purif
revers
phase
flash
chromatographi
follow
condit
column
spheric
g
mobil
phase
water
plu
mm
tfa
mobil
phase
b
acn
flow
rate
mlmin
gradient
b
gradient
min
b
gradient
min
detector
nm
fraction
contain
desir
product
collect
around
b
concentr
reduc
pressur
afford
compound
yield
respect
r
ethoxi
n
yellow
solid
yield
gener
procedur
c
prepar
compound
mixtur
emodin
mmol
dri
dmf
ml
ad
cs
co
mmol
hydroxybromid
iodid
mmol
room
temperatur
stir
h
c
result
mixtur
evapor
reduc
pressur
mix
water
ml
ph
valu
aqueou
phase
adjust
around
hydrochlor
acid
solut
extract
dichloromethan
ml
combin
organ
layer
wash
brine
ml
dri
anhydr
sodium
sulfat
evapor
dryness
crude
product
purifi
silica
gel
column
chromatographi
ethyl
acet
petroleum
afford
compound
total
cell
lysat
cultur
cell
treat
differ
concentr
compound
h
obtain
lyse
cell
icecold
ripa
buffer
pb
sodium
deoxychol
sd
contain
mgml
pmsf
mgml
aprotinin
mgml
leupeptin
mgml
pepstatin
mgml
naf
centrifug
rpm
min
protein
supernat
quantifi
bradford
method
biorad
hercul
ca
usa
use
multimod
varioscan
instrument
thermo
fischer
scientif
waltham
usa
twenti
microgram
protein
per
lane
appli
sd
polyacrylamid
gel
electrophoresi
protein
transfer
polyvinylidin
difluorid
membran
amersham
bioscienc
marlborough
usa
membran
block
room
temperatur
h
tbst
contain
block
powder
santa
cruz
dalla
tx
usa
membran
wash
tbst
min
primari
antibodi
ad
incub
c
overnight
bax
cst
danver
usa
cst
cytochrom
c
cst
abcam
cambridg
usa
abcam
proteintech
group
rosemont
il
usa
gapdh
abcam
antibodi
employ
three
tbst
wash
membran
incub
correspond
horseradish
peroxidaselabel
secondari
antibodi
santa
cruz
room
temperatur
h
membran
wash
tbst
min
five
time
protein
blot
visual
chemiluminesc
reagent
thermo
fischer
scientif
ltd
xray
film
develop
develop
fix
fixer
solut
grey
level
analyz
use
imagequ
la
system
ge
marlborough
usa
cell
treat
indic
concentr
compound
incub
h
cell
wash
twice
icecold
pb
fix
permeabil
ice
cold
ethanol
c
overnight
cell
treat
rnase
c
wash
icecold
pb
final
stain
pi
dark
c
min
cellular
dna
content
cell
cycl
distribut
analysi
perform
system
softwar
cellquest
bd
bioscienc
plot
least
event
per
sampl
percentag
cell
phase
cell
cycl
determin
use
modfit
lt
version
softwar
packag
veriti
softwar
topsham
usa
cell
grown
dmem
medium
contain
growth
factor
cell
densiti
cellsml
h
dispos
ml
plastic
pipett
tip
use
scratch
monolay
cell
streak
motion
compound
ad
streak
cell
cultur
indic
concentr
streak
cell
cultur
serumfre
medium
addit
h
photograph
quantifi
experiment
result
cell
inhibitori
rate
calcul
equat
cell
inhibitori
rate
drug
control
drug
mean
distanc
cell
migrat
drug
group
control
mean
distanc
cell
migrat
control
group
pictur
initi
wound
monolay
compar
correspond
pictur
cell
end
incub
data
present
mean
sd
three
independ
experi
conclus
novel
seri
emodin
deriv
via
introduct
amino
acid
design
synthes
vitro
antiprolifer
test
reveal
deriv
exhibit
moder
potent
antiprolif
activ
cell
cell
among
compound
potent
compound
exhibit
better
select
antiprolif
activ
specif
emodin
display
signific
effect
induc
cell
cycl
arrest
phase
induc
cell
apoptosi
cell
via
releas
cytochrom
c
subsequ
activ
reveal
possibl
molecular
mechan
apoptosi
induct
may
mainli
mitochondri
death
pathway
moreov
compound
also
result
inhibit
cell
migrat
wound
heal
assay
preliminari
molecular
mechan
result
suggest
compound
could
promis
lead
compound
develop
novel
antitumor
drug
potenti
investig
anticanc
drug
supplementari
materi
follow
avail
onlin
http
tabl
biochemistri
analyt
data
three
independ
experi
figur
hnmr
cnmr
fnmr
spectra
compound
